Profound Medical Corp
TSX:PRN

Watchlist Manager
Profound Medical Corp Logo
Profound Medical Corp
TSX:PRN
Watchlist
Price: 10.61 CAD 0.57% Market Closed
Market Cap: 261.7m CAD
Have any thoughts about
Profound Medical Corp?
Write Note

Profound Medical Corp
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Profound Medical Corp
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Profound Medical Corp
TSX:PRN
Total Receivables
$7.2m
CAGR 3-Years
-2%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Total Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Opsens Inc
TSX:OPS
Total Receivables
CA$9.6m
CAGR 3-Years
28%
CAGR 5-Years
25%
CAGR 10-Years
20%
Nanalysis Scientific Corp
XTSX:NSCI
Total Receivables
CA$9.8m
CAGR 3-Years
47%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Theralase Technologies Inc
XTSX:TLT
Total Receivables
CA$569.5k
CAGR 3-Years
39%
CAGR 5-Years
-5%
CAGR 10-Years
0%
MedMira Inc
XTSX:MIR
Total Receivables
CA$1.3m
CAGR 3-Years
10%
CAGR 5-Years
80%
CAGR 10-Years
7%
No Stocks Found

Profound Medical Corp
Glance View

Market Cap
259.8m CAD
Industry
Health Care

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

PRN Intrinsic Value
5.8 CAD
Overvaluation 45%
Intrinsic Value
Price

See Also

What is Profound Medical Corp's Total Receivables?
Total Receivables
7.2m USD

Based on the financial report for Jun 30, 2024, Profound Medical Corp's Total Receivables amounts to 7.2m USD.

What is Profound Medical Corp's Total Receivables growth rate?
Total Receivables CAGR 5Y
22%

Over the last year, the Total Receivables growth was 9%. The average annual Total Receivables growth rates for Profound Medical Corp have been -2% over the past three years , 22% over the past five years .

Back to Top